Processa Pharmaceuticals, the U.S. partner of Yuhan Corp., has released part of the U.S. phase 2a clinical trial result data of YH12852 (PCS12852), a candidate substance to treat gastrointestinal diseases.Yuhan said Thursday that Processa has secured positive clinical results concerning improving ga
Bepirovirsen, which showed a possibility as hepatitis B’s complete cure in the interim analysis of phase 2b clinical trial results in June, saw its efficacy fall by at least 60 in recent data.Still, GSK said it expects Bepiroviren to become a treatment option providing a complete functional cure for
Kuhnil Pharmaceutical said it signed a license and export contract for Rosumega, its dyslipidemia treatment, with Siegfried Rhein, a Mexican pharmaceutical company.Under the accord, Kuhnil will export Rosumega finished products to Mexico through Siegfried Line.Siegfried plans to start the licensing
Celltrion said it recorded 645.6 billion won ($471.4 million) in consolidated sales in the third quarter, up 60.6 percent from a year earlier.The company also registered 213.8 billion won in operating profit, an increase of 28.1 percent.With the cumulative sales up until the third quarter standing a
Shinpoong Pharmaceutical said Thursday it has sought a regulatory nod to change the phase 3 clinical trial plan using Pyramax, its antimalarial treatment, as a Covid-19 treatment.The primary endpoint of the existing clinical trial plan was set up as the proportion of subjects in hospitalization or d
The Korean biopharmaceutical industry is actively recruiting foreign executives to launch their products in the global market.According to industry watchers, Korean biopharmaceutical companies are pursuing new drug development and commercialization overseas rather than in Korea due to excessive dome
Binex was suspended from manufacturing all synthetic drugs at its Busan plant due to violating the Pharmaceutical Affairs Act.Binex maintains that the discipline would have little effect on its marketing. However, given the broad scope of products hit by the administrative disposition, sales losses
Dong-A ST said it plans to incorporate NeuroBo Pharmaceuticals, a U.S. pharmaceutical company, as a subsidiary in December.Dong-A ST plans to finalize the process after becoming the largest shareholder of NeuroBo with a 50.8 percent stake in the company through the latter's extraordinary shareholder
HLB, a biotech firm, said Tuesday that it would apply for conditional permission for its targeted anticancer drug, rivoceranib. HLB, an affiliate of the HLB Group, holds the domestic sales right of rivoceranib.According to industry sources, HLB plans to apply to the Ministry of Food and Drug Safety
Multinational pharmaceutical companies expanded their R&D investment in Korea by 20 percent on-year to 700 billion won ($499.5 million) in 2021, their representative group said Monday.On Monday, the Korea Research-based Pharma Industry Association (KRPIA) published a report on the results of a surve
PHC Corp. (formerly Philosys Healthcare) is suspected of manipulating stock prices by making an announcement related to Covid-19 diagnostic kits. The prosecution has already raided the company, drawing attention to its effects on the resumption of PHC’s stock trading.According to industry sources on
Dong-A ST said on Monday that it signed an exclusive license-out and supply contract with Polifarma, a Turkish pharmaceutical company, for the second-generation anemia treatment, Darbepoetin-α biosimilar, DA-3880.Under the agreement, Dong-A ST will transfer the exclusive development and distribution
Yuhan Corp. said in a regulatory filing on Thursday that its operating profit declined by 43.8 percent year-on-year to 4.5 billion won ($3.15 million) in the third quarter this year. Sales recorded 424.2 billion won, a 2.8 percent fall from the same period last year. Net profit shrank 76.7 percent t
A joint research team led by Gillo Foundation and MedPacto has confirmed that LRRFIP2 protein plays a decisive role in kidney metastasis of gastric cancer cells.In non-metastatic gastric cancer cells, LRRFIP2 (leucine-rich repeat Fli-I-interacting protein 2) protein binds to CARM1 (Coactivator Assoc
Ativa Biotherapeutics, a U.S. affiliate of GC Cell, has withdrawn its initial public offering plan. Accordingly, the company’s listing on the Nasdaq market has also been delayed.According to the U.S. Securities Exchange Commission, Artiva said Tuesday, local time, that it was withdrawing the securit
As the pharmaceutical industry's business market changed to non-face-to-face after the Covid-19 pandemic, multinational pharmaceutical companies have been reorganizing and reducing their workforce on a global scale.In 2021, Lilly Korea, Roche Korea, and Zuellig Pharma Korea cut jobs mainly in sales
Sanofi-Aventis Korea said it would reduce its workforce through a voluntary early retirement program (ERP)."We aim to have an organization that can respond to customer needs more quickly through a more customer-oriented close collaboration system and future core competency development," a Sanofi off
Korea’s major vaccine makers, including SK Bioscience and GC Biopharma, registered disappointing performances in the third quarter.SK Bioscience disclosed its (provisional) third-quarter business results on Monday. According to the public notice, the company’s sales, operating profit, and net profit
LG Chem has acquired the domestic rights for Vimovo (ingredient: naproxen and esomeprazole), an arthritis treatment developed by AstraZeneca.Vimovo is a product launched in Korea by AstraZeneca Korea in 2012, and has been jointly sold by LG Chem since the early stages of the drug's launch.However, A
After the Ministry of Food and Drug Safety pulled a knife again to rectify the practice of "indirect export" by botulinum toxin makers, the stock prices of the three related companies plummeted on Tuesday.As the Korea Exchange (KRX) decided to suspend the companies' stock trading, the incident's rep